Corticosteroids Market Size, Share and Growth Outlook, 2026

Corticosteroids Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Corticosteroids Market size is forecast to increase from $6.15 Billion in 2026 to $9.33 Billion in 2034 at a CAGR of 5.35% between 2026 and 2034.

The Corticosteroids market report provides detailed analysis and outlook of Corticosteroids segments including By Product Type (Glucocorticoids, Mineralocorticoids), By Route of Administration (Oral, Topical, Inhaled, Injectable, Ophthalmic), By Application (Respiratory Diseases, Dermatological Disorders, Rheumatology and Autoimmune Diseases, Endocrinology, Gastroenterology, Oncology Support), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Corticosteroids Industry Overview

Manufacturing Modernization Strengthening Corticosteroid Supply Chains

The corticosteroids industry continues to evolve as pharmaceutical manufacturers invest in production optimization, supply chain resilience, and advanced active pharmaceutical ingredient (API) manufacturing capabilities. Growing demand for corticosteroid therapies across respiratory diseases, autoimmune disorders, dermatological conditions, and inflammatory diseases is driving companies to enhance manufacturing efficiency and secure long-term production capacity. Industry participants are increasingly focusing on operational transformation initiatives, regional manufacturing expansion, and strategic infrastructure investments to support reliable access to essential steroid-based medications.

API Capacity Expansion Supporting Pharmaceutical Production

The production of high-purity steroid and hormone ingredients remains a critical component of the corticosteroids value chain. Euroapi initiated a structural optimization program through its FOCUS-27 transformation strategy, including the divestment of its Haverhill production infrastructure to Particle Dynamics. Simultaneously, the company expanded its participation in the Med4Cure European health sovereignty initiative, which supports investments aimed at strengthening advanced manufacturing and cleanroom production capabilities. These efforts enhance the company's ability to produce a broad portfolio of more than 200 small-molecule APIs, including steroid and hormone compounds that serve as the foundation for numerous corticosteroid therapies.

Sustainability Investments Enhancing Production Resilience

Environmental sustainability and energy security are becoming increasingly important considerations in corticosteroid manufacturing. Sanofi SA advanced industrial sustainability efforts through initial testing of a large-scale biomass boiler facility in France. The project is designed to provide a stable and low-carbon energy source for chemical synthesis and fermentation operations that support the production of glucocorticoid and mineralocorticoid active pharmaceutical ingredients. By reducing dependence on conventional fossil fuel energy sources, manufacturers can improve operational resilience, mitigate exposure to energy market volatility, and support long-term sustainability objectives within pharmaceutical production networks.

Clinical Guideline Updates Driving Demand for Advanced Formulations

Healthcare providers are increasingly adopting standardized treatment protocols for chronic inflammatory and autoimmune conditions, creating additional demand for advanced corticosteroid formulations. Updated clinical practice frameworks issued by major healthcare organizations emphasize the use of targeted and extended-release corticosteroid therapies across oral, injectable, and inhaled administration routes. These recommendations are encouraging pharmaceutical manufacturers to reassess production planning, quality assurance processes, and distribution strategies to ensure uninterrupted product availability. As healthcare systems seek to prevent medication shortages and improve patient outcomes, manufacturers are strengthening compliance monitoring and supply chain management across decentralized production and logistics networks.

Corticosteroids Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Corticosteroids market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Pfizer Inc., Novartis AG, Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd.. The Corticosteroids market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Corticosteroids industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Corticosteroids Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Corticosteroids companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Corticosteroids markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Corticosteroids Market Competitive Benchmarking and Company Analysis

Leading companies in Corticosteroids industry include- Pfizer Inc., Novartis AG, Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd.. The Corticosteroids market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Corticosteroids Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Corticosteroids market remains one of the strongest-performing segments in the country.
The US Corticosteroids Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Corticosteroids market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Corticosteroids industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Corticosteroids markets

Canada's strong Corticosteroids sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Corticosteroids market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Corticosteroids Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Corticosteroids market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Corticosteroids population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Corticosteroids industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Corticosteroids market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Corticosteroids sales through 2034

France Corticosteroids companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Corticosteroids Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Corticosteroids distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Corticosteroids Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Corticosteroids market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Corticosteroids industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Corticosteroids industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Corticosteroids Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Corticosteroids market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Corticosteroids market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Corticosteroids Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Corticosteroids Market Segmentation

By Product Type
Glucocorticoids
Mineralocorticoids
By Route of Administration
Oral
Topical
Inhaled
Injectable
Ophthalmic
By Application
Respiratory Diseases
Dermatological Disorders
Rheumatology and Autoimmune Diseases
Endocrinology
Gastroenterology
Oncology Support
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Top Companies in Corticosteroids Industry

Pfizer Inc.
Novartis AG
Sanofi S.A.
Merck & Co., Inc.
GlaxoSmithKline plc
AstraZeneca
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025